Skip to main content


Fig. 3 | Clinical and Translational Allergy

Fig. 3

From: Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies

Fig. 3

Change in CU-Q2oL Sleep Problems domain. a ASTERIA I, b ASTERIA II, and c GLACIAL. Arrows represent omalizumab dosing. Low numbers represent good quality sleep. Least-squares means were derived from a repeated-measures model adjusted for baseline value (less than median, greater than or equal to median) and baseline weight (<80, ≥80 kg). *p < 0.05; **p < 0.001; ***p < 0.01, versus placebo. CU-Q 2 oL Chronic Urticaria Quality of Life Questionnaire

Back to article page